ArticleCell chemical biology2018
Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity.
Article in Cell chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- All-Hydrocarbon Macrocycle Enables Highly Potent Th1-Biased NKT Cell Agonists for Immunotherapy.JACS Au · 2026Article
- Beyond α-GalCer: Medicinal Chemistry Insights Driving Structural Evolution of CD1d Ligands.Journal of medicinal chemistry · 2026Review
- Development of a Self-Adjuvanting Influenza Peptide-Glycolipid Conjugate Inducing CD8Chembiochem : a European journal of chemical biology · 2026Article
- Development of potential immunomodulatory ligands targeting natural killer T cells inspired by gut symbiont-derived glycolipids.Communications chemistry · 2025Article
- Review
- Can invariant Natural Killer T cells drive B cell fate? a look at the humoral response.Frontiers in immunology · 2025Review
- Stereospecific Synthesis and Biological Evaluation of KRN7000 Analogues with Thio-modifications at the Acyl Moiety.ACS medicinal chemistry letters · 2024Article
- A Humanized Mouse Model Coupled with Computational Analysis Identifies Potent Glycolipid Agonist of Invariant NKT Cells.ACS chemical biology · 2024Article
- Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine.ACS medicinal chemistry letters · 2023Article
- Natural Killer T Cell Diversity and Immunotherapy.Cancers · 2023Review
- mRNA vaccine against malaria tailored for liver-resident memory T cells.Nature immunology · 2023Article
- Gut Microbiota-Derived Unconventional T Cell Ligands: Contribution to Host Immune Modulation.ImmunoHorizons · 2022Article
- 6″-Modifed α-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria.RSC chemical biology · 2022Article
- A humanized mouse model forFrontiers in immunology · 2022Article
- Efficient synthesis of α-galactosylceramide and its C-6 modified analogs.Frontiers in chemistry · 2022Article
- Article
- Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.Cancer research · 2021Article
- Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action.Nature reviews. Chemistry · 2021Review
- Amide-Linked C4″-Saccharide Modification of KRN7000 Provides Potent Stimulation of Human Invariant NKT Cells and Anti-Tumor Immunity in a Humanized Mouse Model.ACS chemical biology · 2020Article
- Natural killer T cell activation increases iNOSJournal for immunotherapy of cancer · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
20 authors at 10 institutions in 4 countries.
Funding
Abstract
Glycosylceramides that activate CD1d-restricted invariant natural killer T (iNKT) cells have potential therapeutic applications for augmenting immune responses against cancer and infections. Previous studies using mouse models identified sphinganine variants of α-galactosylceramide as promising iNKT cell activators that stimulate cytokine responses with a strongly proinflammatory bias. However, the activities of sphinganine variants in mice have generally not translated well to studies of human iNKT cell responses. Here, we show that strongly proinflammatory and anti-tumor iNKT cell responses were achieved in mice by a variant of α-galactosylceramide that combines a sphinganine base with a hydrocinnamoyl ester on C6″ of the sugar. Importantly, the activities observed with this variant were largely preserved for human iNKT cell responses. Structural and in silico modeling studies provided a mechanistic basis for these findings and suggested basic principles for capturing useful properties of sphinganine analogs of synthetic iNKT cell activators in the design of immunotherapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.